Elevance Health stock has delivered a strong 37.8% return over the past year, yet its valuation checks still point to shares looking inexpensive on several fronts. This raises the question of whether the recent pullback has left the stock trading below what its fundamentals may support.

• The 37.8% gain over the last 12 months signals that Elevance Health has already rewarded shareholders. Any further upside case now rests more on valuation support than on a rerating from depressed levels.
• Recent updates around earnings power and margin pressure can support a view that profitability may improve over time, while continued membership declines and higher medical benefit costs remain a key risk to how much value investors ultimately assign to the stock.
• With Elevance Health screening as undervalued in 6 of 6 core valuation checks, the broader picture currently leans toward the shares pricing in cautious expectations rather than optimism.

The issue now is whether Elevance Health’s recent selloff and high valuation score leave enough upside potential to justify the risks around margins and membership trends.

Is Elevance Health Still Cheap on Earnings?

The P/E ratio is a useful yardstick for Elevance Health because earnings remain a central focus for investors watching margins and membership trends.

Elevance Health trades on a P/E of about 16.3x, which sits below the Healthcare sector average of 26.0x and the broader peer group near 41.9x. On a tailored basis, the stock also screens below a modelled fair P/E of 33.9x, which reflects what investors might typically pay given Elevance Health’s size, quality profile, and risk factors.

Despite the recent EPS guidance updates and ongoing margin concerns highlighted in recent results, the current P/E indicates that Elevance Health is priced at a discount to sector and peer benchmarks. The gap between the current multiple and the modelled fair ratio suggests the market is assigning cautious expectations rather than paying a higher price for potential earnings power.

On the P/E multiple, Elevance Health stock appears inexpensive relative to both industry norms and a more tailored fair value range.

The Elevance Health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Elevance Health take the valuation gap you have just seen and translate it into clear, competing stories about what would need to happen to Elevance Health's growth, margins, and earnings for the stock to be worth materially more or less than its current price, and they sit on the company’s Community page. Each one treats fair value as a thesis about Elevance Health's business that can be revisited over time, rather than a one off snapshot.

Community views on Elevance Health are split, with one camp focused on margin recovery potential and the other on government plan and regulatory risk.

Bull case: 15% undervalued

"The company is aggressively leveraging advanced analytics, digitization, and AI-enabled tools to streamline clinical workflows, automate processes, reduce fraud, and improve cost management..."

Bear case: 13% overvalued

"Even though the company is exercising disciplined pricing and investment in operational improvements, heavy exposure to government-backed business exposes Elevance Health to reimbursement risk, political uncertainty, and delays in rate alignment..."

Do you think there's more to the story for Elevance Health? Head over to our Community to see what others are saying!

The Bottom Line

For Elevance Health, the key takeaway is that the market-multiple checks still point to an undervalued stock, despite recent concerns around margins and membership trends. The valuation gap versus sector and peer benchmarks suggests investors are not paying up for potential earnings strength, and are instead pricing in a cautious outlook.

What matters most from here is whether Elevance Health can stabilise profitability and medical cost trends enough to convince the market that this discount is too wide. The crux of the debate is whether the current lower P/E reflects an opportunity or a fair response to ongoing execution and regulatory risks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.